Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that the European Medicines Agency (EMA) has issued a positive opinion for orphan drug designation for tamibarotene, aimed at treating myelodysplastic syndrome (MDS). This designation follows the FDA's granting of the same status in February 2022. Tamibarotene is currently being evaluated in the SELECT-MDS-1 Phase 3 trial alongside azacitidine for higher-risk MDS patients. Results from this trial are due in late 2023 or early 2024, with a potential new drug application filing anticipated next year.
Syros Pharmaceuticals (NASDAQ:SYRS) announced a live conference call and webcast on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a corporate update. Investors can access the call by dialing (833) 636-1323 domestically or (412) 902-4279 internationally, or via its website. Syros is focused on developing innovative medicines that control gene expression, with a robust pipeline including tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, among other candidates.
Syros Pharmaceuticals announced a merger agreement to acquire TYME Technologies, gaining approximately
Syros Pharmaceuticals (NASDAQ: SYRS) announced the grant of restricted stock units (RSUs) for 48,400 shares to two new employees as an employment inducement per Nasdaq Listing Rule 5635(c)(4). The RSUs vest annually over four years, contingent on continued service. Syros is focused on gene expression control, advancing a clinical pipeline that includes tamibarotene for myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for select solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 15 at 9:30 a.m. ET, held at The Lotte New York Palace, NY. Attendees can join via a live webcast on Syros's website, with an archived replay available for 30 days. Syros focuses on developing medicines that control gene expression for diseases like myelodysplastic syndrome and leukemia, with a clinical pipeline that includes innovative treatments such as tamibarotene and SY-2101.
Syros Pharmaceuticals (NASDAQ: SYRS) has granted an aggregate of 77,850 restricted stock units (RSUs) to four new employees, effective May 31, 2022. These RSUs serve as material inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, subject to the employees’ continued service. Syros aims to leverage its gene control technology in advancing treatments for certain cancers, with a clinical pipeline that includes innovative therapies like tamibarotene and SY-5609.
Syros Pharmaceuticals (SYRS) reported Q1 2022 revenues of $5.5 million, up from $4.8 million in Q1 2021. The company reported a net loss of $25.1 million or $0.40 per share, compared to a loss of $14.2 million or $0.23 per share in the prior year. Key developments include ongoing trials: SELECT-MDS-1 with expected data in Q4 2023/Q1 2024, and SELECT-AML-1 Phase 2 due in the second half of 2022. The company deprioritized SY-5609 in hematologic malignancies due to current market conditions and plans to secure additional capital before advancing SY-2101 into Phase 3.
Syros Pharmaceuticals (SYRS) announced a live conference call and webcast for May 16, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and provide corporate updates. Investors can access the call via telephone (866-595-4538 domestic) or through the company's website. Syros focuses on developing small molecule medicines that manipulate gene expression and has a pipeline featuring tamibarotene for myelodysplastic syndrome and leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors and blood cancers.
Syros Pharmaceuticals (NASDAQ: SYRS) has granted 136,750 restricted stock units (RSUs) to six new employees as part of their employment agreement, complying with Nasdaq Listing Rule 5635(c)(4). These awards will vest quarterly, starting April 30, 2023, contingent on continued employment. Syros is focused on developing innovative gene expression medicines, with a pipeline that includes tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors and blood cancers.
Syros Pharmaceuticals (SYRS) announced promising preclinical results for its CDK12 inhibitor program, showcasing strong anti-tumor activity in breast, lung, and ovarian cancer models. The data, presented at the AACR Annual Meeting 2022, indicate that the CDK12 inhibitors have low nanomolar potency and selectivity against other CDKs. The inhibitors demonstrated significant tumor regression in animal models and synergy with DNA damaging agents. Syros plans to nominate a development candidate in the second half of 2022, targeting patients resistant to current therapies.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
